Literature DB >> 25323689

New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor.

Florence Beckerich1, Christophe Hézode2, Christine Robin1, Jean-Louis Beaumont3, Eric Gautier4, Sébastien Maury1, Catherine Cordonnier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25323689      PMCID： PMC4199962          DOI： 10.1182/blood-2014-06-582122

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy.

Authors:  P Ljungman; A Locasciulli; V G de Soria; A N Békássy; L Brinch; I Espigado; A Ferrant; I M Franklin; J O'Riordan; M Rovira; P Shaw; H Einsele
Journal:  Bone Marrow Transplant       Date:  2011-12-12       Impact factor: 5.483

2.  No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.

Authors:  M Tomblyn; M Chen; M Kukreja; M D Aljurf; F Al Mohareb; B J Bolwell; J-Y Cahn; M H Carabasi; R P Gale; R E Gress; V Gupta; G A Hale; P Ljungman; R T Maziarz; J Storek; J R Wingard; J-A H Young; M M Horowitz; K K Ballen
Journal:  Transpl Infect Dis       Date:  2012-05-01       Impact factor: 2.228

3.  Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation.

Authors:  Sri Naveen Surapaneni; Parameswaran Hari; Josh Knox; Jack Daniel; Kia Saeian
Journal:  Am J Gastroenterol       Date:  2006-11-13       Impact factor: 10.864

4.  Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon.

Authors:  E A Vance; R J Soiffer; G B McDonald; D Myerson; J Fingeroth; J Ritz
Journal:  Transplantation       Date:  1996-11-15       Impact factor: 4.939

5.  Long-term outcome of hepatitis C infection after bone marrow transplantation.

Authors:  Régis Peffault de Latour; Vincent Lévy; Tarik Asselah; Patrick Marcellin; Catherine Scieux; Lionel Adès; Richard Traineau; Agnès Devergie; Patricia Ribaud; Hélène Espérou; Eliane Gluckman; Dominique Valla; Gérard Socié
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

6.  Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course.

Authors:  M C Shuhart; D Myerson; B H Childs; J D Fingeroth; J J Perry; D S Snyder; C L Spurgeon; C A Bevan; G B McDonald
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

7.  Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Authors:  Eduardus F M Posthuma; Erik W A F Marijt; Renee M Y Barge; Ronald A van Soest; Inge O Baas; C W J Ingrid Starrenburg; Shama L van Zelderen-Bhola; Willem E Fibbe; Wim M Smit; Roel Willemze; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

8.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Authors:  Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

9.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Authors:  Anuoluwapo Osinusi; Eric G Meissner; Yu-Jin Lee; Dimitra Bon; Laura Heytens; Amy Nelson; Michael Sneller; Anita Kohli; Lisa Barrett; Michael Proschan; Eva Herrmann; Bhavana Shivakumar; Wenjuan Gu; Richard Kwan; Geb Teferi; Rohit Talwani; Rachel Silk; Colleen Kotb; Susan Wroblewski; Dawn Fishbein; Robin Dewar; Helene Highbarger; Xiao Zhang; David Kleiner; Brad J Wood; Jose Chavez; William T Symonds; Mani Subramanian; John McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyamasundaran Kottilil
Journal:  JAMA       Date:  2013-08-28       Impact factor: 56.272

10.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245
  10 in total
  1 in total

1.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.